Little-known biotech's shares double after cancer drug trial wins

Genmab's shares have doubled in three months following a string of cancer drug trial wins, according to CNBC. The company is also pushing to own more of the medicines it develops.

Timeline

1. 3 Nov, 09:35 UTCCNBC reports Genmab shares doubled

Top sources

• A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBC